Ex-Novartis exec sets out to create ‘Apple of AI’

Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.

By Kelly Bilodeau • March 18, 2024

5 Big Pharma CEOs who saw major pay bumps in 2023

Pharma’s recent wins have led to pay windfalls for several company leaders.

By Amy Baxter • March 18, 2024

Explore the Trendline➔

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.  

By PharmaVoice staff

After Amylyx drug failure, what’s next for ALS?

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

By Meagan Parrish • March 15, 2024

Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

By Michael Gibney • March 14, 2024

As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

By Alexandra Pecci • March 12, 2024

The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

By Michael Gibney • March 12, 2024

Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D

The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.

By Kelly Bilodeau • March 11, 2024

COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter

With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.

By Amy Baxter • March 11, 2024

Why pharma should prioritize the patient journey: A survivor’s story

One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.

By Carolyn Zele, Solution Consulting Advisor, MMIT • March 11, 2024

Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

By Meagan Parrish • March 8, 2024

Amylyx ALS drug fails crucial study, putting company’s future in doubt

The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

By Jacob Bell • Updated March 8, 2024

J&J’s growing rare disease focus brings a potential multi-use treatment to the table

The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.

By Michael Gibney • March 7, 2024

Could pharma’s legal attack on the IRA succeed in killing price negotiations?

An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.

By Amy Baxter • March 6, 2024

Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches

Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.

By Kelly Bilodeau • March 6, 2024

HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

By Michael Gibney • March 5, 2024

After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections

Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.

By Amy Baxter • March 1, 2024

A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain

How research companies can shift strategies to attract and retain the staff that keeps trials humming along. 

By Kelly Bilodeau • Feb. 28, 2024

Can a top scientist and Moderna co-founder change the CRO game?

From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

By Michael Gibney • Feb. 28, 2024

Behind a big-name rare disease biotech, an exec draws from personal experience

The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

By Alexandra Pecci • Feb. 27, 2024

How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues

Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

By Alexandra Pecci • Feb. 26, 2024

AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

By Michael Gibney • Feb. 22, 2024

4 biotechs to watch in 2024

A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

By Alexandra Pecci • Feb. 21, 2024

Biden or Trump: How deeply will 2024’s election outcome impact pharma?

The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

By Michael Gibney • Feb. 20, 2024

Kite’s next-gen CAR-T aims include quicker production and more disease targets

While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

By Kelly Bilodeau • Feb. 20, 2024

Value and potential of IoT and AI for chronic diseases treatment

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024